Novartis will it go Pfizer and Abbott way!

Last year Abbott went ahead with a spin off into two major business units, following that for Pfizer speculation started to surface that it is also going for Split off in early Jan 2013, but yes the decision came in July about splitting of the company. Now it’s turn for Novartis as the CEO announced that he is certainly going to make some changes.....what we have to see if Chiron will still exist in the port folio or they will merge it with Pharma Biological and Vaccine innovation research....time will tell what will be the next steps for Novartis

Pfizer's Next Move.......After RA...its Oncology and Metabolic disorders.............

Pfizer has always been the company which intrigued me in many ways......the company which acted as a massive shark for quite long is being quite mum for a while....In Jan there was a buzz that the company is splitting its business in the similar ground to Abbott but there were no initiation activity from the company end. And then there aggressive movement in the Metabolic and immunology segment (Many of the compounds in Phase I/II) we still need need to check the company strategy going forward.....After its nutrition business sales it has cash in hand....will it go for Onyx deal to expand its portfolio in Oncology, as recently it collaborated for Cytomax for its ADC technology.........Will Oncology be the next game changer for Pfizer growth the way it has been for Roche?????.....Will it be able to displace Roche products in some oncology segments the way it’s trying hard to displace Humira in RA with its expected block buster product???????

Many things to watch from Pfizer's end!

Modern Healthcare touching millions of lives in India

In the last few years India as a favorable destination for medical treatment options as the hospital chains in India has well equipped themselves with facilities second to none. With blooming economy we can boasts of highly qualified doctors with specialization in different branches of medical science. Major advantage of being in India is the cost-effectiveness of treatments. Estimates claim that treatment costs in India start at around a tenth of the price of comparable treatment in developed countries, thus the healthcare system developed in India not only supports Indian patients but treatment spreads to all across globes including America’s and Europe

Major advantages of healthcare treatment options in India include:

ü  Low-cost medical treatment

ü  High-quality medical care

ü  Low TAT (Turn around time)

ü  Places of interest

ü  English-speaking staff

The hospitals chains (Both private, semi government hospitals are promoting themselves by believing in the mission of

·       -  Better Life: Consistently delivering compassionate care to the patients throughout their lives by the value of Seva and “Patient first” approach

·      -   Better Care: All the major hospital have take ISO certification which includes their being protocol driven, reflecting global best practices, and ensure that their patients consistently receive quality care all throughout their lives. 

·       -  Outstanding facility and services: All the facilities have been designed and implemented by international experts to meet the highest international standards of effective medical flows, patient safety, healing and comfort.

·         Innovation: leveraging technology to enhance patient care and outcomes. 

·      -   A legacy of Seva/Care: Hospital chains like Apollo hospital believe in the vision of “Touch a billion lives to create a better world and this is embedded in their genes and their philanthropic endeavors have touched more than 12 million lives till date 

·         -Value and relationship: The values ensure that everyone who enters the front door can count on the highest standards of values and a long-term relationship for rest of their lives

·        - Affordable excellence: Hospitals do understand that modern healthcare is expensive but all the hospitals are focused on being more affordable to their consumers providing them equivalent quality.

We see that all the major hospital chains in India are promoting these values all across the board; I believe that in a decade we will see a healthier India going forward as the legacy of seva, value, relationship and affordable excellence in going to increase day by day  

Biosimilars....

After my M Tech from BITS Pilani, i got placed with biotech pharma R&D where in i was asked to choose my task from being a molecular biologist to fermentation and further downstream processing. I chose to be a molecular biologist, then went ahead for Pharma consulting and the journey still continues. I have been working in the Biosimilar arena for around 8 years with experience in working in R&D to CI in terms of PMR services in terms of development of specific recombinant proteins and Mabs

In the late 2000's some big pharma companies showed a big picture to the world related to their huge investment in this arena and there were some who slowly started developing their pipeline. With the block buster era loosing its glory...biosimilars will mark the difference and emerging markets will be the bait for the big pharma's....in present Europe has been the front runner for biosimilar promotion but we can't negate the emerging markets (China, India and South Korea).....they are the new junctures for growth and promotions of biosimilars and will emerge as destination for biosimilar developments.......

After Daniel Vasella.......will Novartis maintain its Charm???

I have read a lot about Daniel Vasella, how he changed the fortune of Novartis,.......In Basel two companies campuses are looked for, one is Roche and another is Novartis.......Both with different work style and generally people tell me that none of the companies recruit other's employees......I am unable to confirm it.....but working in Novartis Basel office is a different ball game.......

Daniel Vasella was the man who made a difference for the company and some analyst reports have predicted that Novartis will be heading for number 1 position in terms of Pharma revenues by year 2018......the recent news of Daniel Vasella quitting as CEO was shocking for me......according to report investors were happy with the decision but we have to see how the market is going to behave further....what will be companies new M&A and R&D policies......time will say if Novartis will maintain its charm? 

Parexel!

Parexel just went into buying out and expending its portfolio in Regulatory approval processes. Though Quintile always had the first mover advantage and icon the smallest baby in the industry has matured quite fast. What i have observed is that PPD and Parexel have slight conservative approach compared to Quintiles and Icon in terms of their portfolio expansion and establishment in new territories. Like Quintiles new move in Biosimilars and RA therapy as such. Parexel went on to penetrate in the field of Biosimilars but more to watch from this CRO in terms of its strategic expansion in APAC, Middle east and Latin America

Whistleblower!

After the provisions in the whistle blower act, pharma has seen many illegal marketing tactics coming out in public, Pfizer has been targeted many a times and it’s still with its competitor Novartis considered the best in the field of Pharma Marketing

We now need to watch how Pfizer is promoting Tofacitinib and Eliquis?

Last month what astonished me that Amgen was ready to pay back around 750 M USD to federal government as it already knew that it had to pay the price for use of illegal marketing tactics for Arnasep. This is not the first case, for the past 20 years we have seen a tremendous increase in these types of marketing tactics by Pharma and biopharma companies to allure physicians and primary health bodies. As Amgen had already kept aside 750 M USD from its revenue. Going forward we will observe that companies as part of their marketing budget will keep additional 1B USD in cash for these type of situations.

As whistleblower act has been promoted in US we have more to watch!